Comparison
Alpha-Lipoic Acid vs Vitamin D3 + K2
Side-by-side of Alpha-Lipoic Acid and Vitamin D3 + K2. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-Lipoic Acid
Alpha lipoic acid supplement guide: 600 mg/day oral dosing, R-ALA vs racemic absorption, neuropathy trial data, antioxidant mechanism, interactions.
Vitamin D3 + K2
Vitamin D3 K2 supplement profile: cholecalciferol at 1000-4000 IU/day corrects deficiency, MK-7 directs calcium to bone, away from arteries.
Effects at a glance
Alpha-Lipoic Acid
- •Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
- •Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
- •R-ALA enantiomer absorbs 40-100% better than racemic mixtures
- •Activates AMPK; produces small HbA1c reductions in T2DM
- •Plasma half-life ~30 minutes; split dosing or sustained-release is standard
- •Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required
Vitamin D3 + K2
- •Reduces non-vertebral fractures 10-20% in older adults at 800 IU/day or above when combined with calcium
- •VITAL trial showed neutral results on primary CV and cancer endpoints at 2000 IU/day over 5 years
- •Vitamin D supplementation reduces respiratory infection incidence ~10-20% in deficient populations
- •K2 MK-7 has 72-hour plasma half-life vs 1-2 hours for MK-4; once-daily dosing is sufficient
- •Synergy hypothesis is largely preclinical; dedicated combination RCTs are limited
- •Daily dosing outperforms bolus dosing for immune and infection outcomes
Side-by-side
| Attribute | Alpha-Lipoic Acid | Vitamin D3 + K2 |
|---|---|---|
| Category | supplement | supplement |
| Also known as | ALA, thioctic acid, R-ALA, R-lipoic acid | cholecalciferol + menaquinone, D3/K2, vitamin D3 with MK-7 |
| Half-life (hr) ↗ | 0.5 | 360 |
| Typical dose (mg) ↗ | 600 | 0.05 |
| Dosing frequency | 1 to 3 times daily on empty stomach | daily with a fat-containing meal |
| Routes | oral, iv | oral |
| Onset (hr) | 0.5 | 24 |
| Peak (hr) | 1 | 168 |
| Molecular weight | 206.33 | 384.64 |
| Molecular formula | C8H14O2S2 | C27H44O (D3); C46H64O2 (MK-7) |
| Mechanism | Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. | D3 converts to calcidiol then calcitriol, activating the vitamin D receptor (VDR) to increase intestinal calcium absorption and modulate immune and bone gene transcription. K2 carboxylates osteocalcin and matrix Gla protein, directing calcium toward bone and inhibiting vascular calcification. |
| Legal status | Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany | Dietary supplement (global) |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | Not scheduled |
| Pregnancy | Insufficient data; precautionary avoidance | Recommended at standard doses for fetal bone development; consult clinician at higher doses |
| CAS | 62-46-4 | 67-97-0 |
| PubChem CID | 864 | 5280795 |
| Wikidata | Q161227 | Q139347 |
Safety profile
Alpha-Lipoic Acid
Common side effects
- nausea
- abdominal discomfort
- diarrhea
- sulfurous odor
- rash (rare)
Contraindications
- pregnancy and lactation (insufficient safety data)
- active insulin autoimmune syndrome predisposition
Interactions
- insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
- thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
- biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
- iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Vitamin D3 + K2
Common side effects
- GI upset at high doses
- headache (rare)
- hypercalcemia (only at sustained very high D3 doses)
Contraindications
- hypercalcemia
- sarcoidosis
- active hyperparathyroidism
- warfarin therapy (K2 component requires stable intake)
Interactions
- warfarin: K2 component can affect anticoagulation; maintain stable intake and inform anticoagulation clinic(moderate)
- thiazide diuretics: additive calcium retention; hypercalcemia risk with high-dose D3(moderate)
- digoxin and calcium channel blockers: additive effects from D3-induced hypercalcemia(moderate)
- glucocorticoids: reduced vitamin D efficacy and bone effects(moderate)
- cholestyramine and orlistat: bind fat-soluble vitamins; separate dosing by 2 to 4 hours(moderate)
Which Should You Take?
Vitamin D3 + K2 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Alpha-Lipoic Acid is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Alpha-Lipoic Acid.
- → If your priority is long-term neuroprotection, pick Alpha-Lipoic Acid.
- → If your priority is bone density, pick Vitamin D3 + K2.
- → If your priority is cardiovascular health, pick Vitamin D3 + K2.
Edge case: Half-lives differ materially (Alpha-Lipoic Acid ~0.5 hr vs Vitamin D3 + K2 ~360 hr). Vitamin D3 + K2 reaches steady state faster; Alpha-Lipoic Acid is easier to dial in if tolerability is uncertain.
Default choice: Vitamin D3 + K2. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Alpha-Lipoic Acid only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-Lipoic Acid and Vitamin D3 + K2?
Alpha-Lipoic Acid and Vitamin D3 + K2 differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-Lipoic Acid or Vitamin D3 + K2?
Alpha-Lipoic Acid half-life is 0.5 hours; Vitamin D3 + K2 half-life is 360 hours.
Can you stack Alpha-Lipoic Acid with Vitamin D3 + K2?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper